Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions
about
Immuno-intervention for the induction of transplantation tolerance through mixed chimerismImmune Reconstitution after Allogeneic Hematopoietic Stem Cell TransplantationSeparating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptorsNaturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection.Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantationVisualization of immune response kinetics in full allogeneic chimeras.Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.Rapid Functional Decline of Activated and Memory Graft-versus-Host-Reactive T Cells Encountering Host Antigens in the Absence of Inflammation.Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissuesImmune tolerance: mechanisms and application in clinical transplantation.Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras.Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantationHematopoietic cell transplantation for tolerance induction: animal models to clinical trialsReview of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer.The allogeneic graft-versus-cancer effect.IL-12hi rapamycin-conditioned dendritic cells mediate IFN-γ-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease.Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus TumorAllogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Prevention of GVHD without losing GVL effect: windows of opportunity.Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.Immunotherapy in acute myeloid leukemia.Induction of tolerance through mixed chimerism.The role of dendritic cells in graft-versus-tumor effectImmune tolerance in recipients of combined haploidentical bone marrow and kidney transplantation.5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity.CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy.Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation.Langerhans cells regulate cutaneous injury by licensing CD8 effector cells recruited to the skinThe role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.Tumor rejection effects of allorestricted tumor peptide-specific CD4(+) T cells on human cervical cancer cell xenograft in nude mice.Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT.
P2860
Q27001243-C8B35B0E-B4E2-4747-BD0E-4C36B850B749Q28072627-D13F2214-AED0-4BB5-96A0-E04747FA46F0Q33685495-75DA0ACE-6E58-4A34-8410-EB83DED727F8Q33707475-1633B27E-C4A3-4837-977D-0603A51B0103Q34245299-35AE1E71-A22A-4013-BF20-7DA1C34A77CCQ34309388-D5727399-1C61-4009-996A-36642CCB6E9CQ34352679-2E82E080-89AB-4301-A477-17D63A12C2E5Q35585983-1524F184-44B4-477E-A6C6-4BCFEAEF80CCQ35591430-9956B09F-48E0-447E-ACB3-9633780F44C4Q35799360-F0ACB54F-6BEB-4347-BD39-2D4B65810EC6Q35824974-4FE18831-61D6-47BA-A1AC-84D45B7278CBQ35828638-3BABE456-C4D9-436A-9125-762CC0932B97Q35864495-B06C8BF4-F0FC-4985-B86C-4D90B3B9BD0AQ35909695-CD7B3AF1-C8A3-4840-BE52-134C5A1C26F5Q36014986-73498858-EAC6-46E1-A3C0-D36D199D796BQ36228795-3FA2913D-2CAD-464E-AB6F-112465CA9572Q36909564-001BBECC-92E4-493F-84B8-B7257BB7E66EQ37176587-49C4EBA8-9202-451A-9802-2C30F117F1E7Q37191056-48200F1C-491E-4414-A416-43F599013A1EQ37211290-FFDF0F0E-8305-44F3-984A-4F284E658577Q37235132-E88DD267-C391-48F5-AFC1-5F2821D66B53Q37388414-EA4A75BF-D875-424A-9B2B-A259D5430407Q37522583-1024566D-4B43-4361-9EB1-7BA0B27F44D9Q37593125-4553F733-B3C3-499E-8A16-B73725FB2660Q37661441-D9372695-501F-4192-80EA-41AF13CCD71EQ37718563-7AC5ECC4-3B91-4105-ACAC-25B3EDC01143Q37810098-FFD1F73E-38FC-4548-A0C9-E8EE51F1A1AEQ37817036-6E3F7AF4-C0E1-43EE-9C3D-6DF025F933B5Q37894465-7525CBBD-FA4C-4CDA-890C-EC2951998D8DQ38171574-59EF60C9-6B1B-4EA3-AD27-46E44B080291Q38175306-D8C129D5-BEBA-4851-ADDE-80DAD313AD4CQ38193807-47B1FCCB-02D2-4651-9A84-072ECF7FC1D8Q38514510-B34F1596-34DC-4656-82EE-E7BE29D69AA9Q38626158-DAD52E8B-0A27-46EB-A739-FC1C2A7CE918Q41480472-E6912751-DA1B-450C-873C-F2EA94CAC981Q41577518-6F26A54E-4BEB-4091-926A-676D2701E032Q42135895-6B57F18A-2B2D-4C85-8F53-929E491730AFQ42151172-989465B5-D81C-4488-9FDA-65CC40495721Q44473706-5228B92B-A4E3-468E-BE46-7C9EFA56B9F4Q46101422-430B7567-486B-4568-ABE1-528483F090E6
P2860
Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Host MHC class II+ antigen-pre ...... ayed donor leukocyte infusions
@ast
Host MHC class II+ antigen-pre ...... ayed donor leukocyte infusions
@en
type
label
Host MHC class II+ antigen-pre ...... ayed donor leukocyte infusions
@ast
Host MHC class II+ antigen-pre ...... ayed donor leukocyte infusions
@en
prefLabel
Host MHC class II+ antigen-pre ...... ayed donor leukocyte infusions
@ast
Host MHC class II+ antigen-pre ...... ayed donor leukocyte infusions
@en
P2093
P2860
P1433
P1476
Host MHC class II+ antigen-pre ...... ayed donor leukocyte infusions
@en
P2093
Guiling Zhao
Hyeon-Seok Eom
Jennifer Buchli
Jessica Sachs
Megan Sykes
Pete Cotter
Richard Hsu
P2860
P304
P356
10.1182/BLOOD-2006-03-007427
P407
P577
2006-06-06T00:00:00Z